Unknown

Dataset Information

0

Open-label pilot study of lisdexamfetamine for cocaine use disorder.


ABSTRACT: Background: Cocaine use disorder (CUD) is a substantial public health problem with no FDA-approved medication treatments. Psychostimulants have shown promise as pharmacotherapy for CUD. Lisdexamfetamine, a novel prodrug psychostimulant, is roughly 40-50% as potent as dextroamphetamine.Objectives: To evaluate the safety, tolerability, and optimal dosing of lisdexamfetamine for treating CUD.Methods: Open-label, 8-week trial of 17 CUD adults. Participants were titrated to the maximum tolerated dose of 140 mg over 2-week period and maintained for 4 weeks, followed by a two-week taper period. The primary outcome measures were the maximum daily dose achieved during the study period and tolerability as measured by medication-related study drop-out.Results: Among the 16 participants with post-enrollment data, the mean dose of lisdexamfetamine achieved was 118.1 mg (standard deviation (SD) = 40.4), mean retention was 6.5 weeks (SD = 2.0), and no participants discontinued study medication due to adverse effects. Four participants had dose reductions due to adverse effects and continued in the trial. Six participants (37.5%) were abstinent for the last 3 weeks of their study participation. Mean dollars of cocaine spent per day significantly decreased from $19.72 at baseline to $7.57 during the last 3 weeks of study participation (t15 = 3.60, p = .003). The mean percent of using days significantly decreased from 25% at baseline to 12% during the last 3 weeks of study participation (t15 = 3.33, p = .005).Conclusion: The use of lisdexamfetamine for CUD in doses ranging to 140 mg daily was safe and generally well tolerated.

SUBMITTER: Mariani JJ 

PROVIDER: S-EPMC8266739 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4509923 | biostudies-literature
| S-EPMC6039401 | biostudies-literature
| S-EPMC5843702 | biostudies-literature
| S-EPMC5976689 | biostudies-literature
| S-EPMC5044471 | biostudies-literature
| S-EPMC8971990 | biostudies-literature
2017-08-23 | GSE80342 | GEO
| S-EPMC5158093 | biostudies-literature
| S-EPMC5400413 | biostudies-literature
| S-EPMC4199242 | biostudies-literature